Library · Brain & nerves · Growth hormone stimulation and release
CJC-1295 (with and without DAC)
Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC, CJC-1295 DAC, tetrasubstituted GRF (1-29)
Long-acting synthetic analog of growth hormone-releasing hormone, shown in early studies to raise GH and IGF-1 levels. Not FDA-approved for any use, with no major 2020–2025 trials; banned by WADA and sold as a research chemical, though a 2024 FDA status review opened it to further compounding evaluation without approving it.
Research score 40/100. Reference only, not a dose.
- Growth Hormone Release
- Muscle Growth
- Fat Loss
- Recovery Enhancement
- Sleep Improvement
- US status
- Research Chemical
- Approval
- Not FDA Approved; Prohibited by WADA. Re-evaluated by FDA in 2024 for potential compounding.
- Evidence
- No active or recent clinical trials. Early-phase studies were conducted prior to 2020 but did not lead to clinical approval.
- Research score
- 40 / 100
- Indication
- Research Only - No Medical Indication
- Origin
- Canada
- Source category
- Brain & Nervous System
- Status group
- Research chemical
Mechanism
Binds GHRH receptors on the pituitary to trigger GH release via cAMP signaling. The DAC version attaches to serum albumin, extending its half-life from about 30 minutes to 6–8 days for sustained GH/IGF-1 elevation; the non-DAC form (Mod GRF 1-29) acts more briefly.
Safety file
Long-term human safety is unknown. The FDA has flagged cardiac event risk, plus concerns tied to elevated GH/IGF-1, including insulin resistance.
- Injection site reactions
- Temporary numbness in extremities
- Water retention
- Headache
- Joint stiffness
- Increased insulin resistance